The PCSK9 decade: Thematic Review Series: New Lipid and Lipoprotein Targets for the Treatment of Cardiometabolic Diseases |
| |
| Authors: | Gilles Lambert Barbara Sjouke Benjamin Choque John J P Kastelein G Kees Hovingh |
| |
| Institution: | *Laboratoire Inserm U957, Université de Nantes, Faculté de Médecine, Nantes, France;†Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands;§The Heart Research Institute, Lipid Research Group, Sydney, New South Wales, Australia |
| |
| Abstract: | PCSK9 proprotein convertase subtilisin/kexin type (PCSK9) is a crucial protein in LDL cholesterol (LDL-C) metabolism by virtue of its pivotal role in the degradation of the LDL receptor. In recent years, both in vitro and in vivo studies have greatly supplemented our understanding of the (patho)physiological role of PCSK9 in human biology. In the current review, we summarize studies published or in print before May 2012 concerning the physiological role of PCSK9 in cholesterol metabolism. Moreover, we briefly describe the clinical phenotypes encountered in carriers of mutations in the gene encoding PCSK9. As PCSK9 has emerged as a novel target for LDL-C lowering therapy, methods to inhibit PCSK9 will also be reviewed. Initial data from investigations of PCSK9 inhibition in humans are promising and indicate that PCSK9 inhibition may be a viable new therapeutic option for the treatment of dyslipidemia and associated cardiovascular diseases. |
| |
| Keywords: | antibodies cholesterol drug therapy low density lipoprotein metabolism lipoprotein receptors proprotein convertase subtilisin/kexin type 9 |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
